Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Incorrect headline could be cause of Selecta weakness, says Cantor Fitzgerald » 16:02
07/22/21
07/22
16:02
07/22/21
16:02
SELB

Selecta Biosciences

$3.36 /

-0.465 (-12.17%)

, MCRB

Seres Therapeutics

$8.46 /

-12.335 (-59.32%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska notes that Seleta Biosciences (SELB) shares have been trading down on Thursday, despite the company not reporting any news-related items. The analyst thinks shares are trading down as a result of a Bloomberg article highlighting the setback reported in the microbiome space from Seres (MCRB). Kluska says "the article incorrectly lists Selecta Biosciences as a related ticker." as Selecta is "not a microbiome-based company." Overall, the analyst sees "no fundamental reasons" for the weakness in the shares and reiterates an Overweight rating and a price target of $9 on the stock.

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.36 /

-0.465 (-12.17%)

MCRB Seres Therapeutics
$8.46 /

-12.335 (-59.32%)

SELB Selecta Biosciences
$3.36 /

-0.465 (-12.17%)

06/14/21 BTIG
Selecta Biosciences initiated with a Buy at BTIG
04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
MCRB Seres Therapeutics
$8.46 /

-12.335 (-59.32%)

07/22/21 JMP Securities
Seres trial news 'disappointing,' but an isolated story, says JMP
07/22/21 Piper Sandler
Piper trims Seres Therapeutics price target to $32, would buy on weakness
07/22/21 Cowen
Seres Therapeutics' Phase IIb study fails to demonstrate efficacy, says Cowen
07/09/21 Chardan
Seres Therapeutics assumed with a Buy at Chardan
SELB Selecta Biosciences
$3.36 /

-0.465 (-12.17%)

MCRB Seres Therapeutics
$8.46 /

-12.335 (-59.32%)

  • 13
    Aug
MCRB Seres Therapeutics
$8.46 /

-12.335 (-59.32%)

Over a week ago
Hot Stocks
Selecta Biosciences appoints Nishan de Silva to board of directors » 08:18
06/24/21
06/24
08:18
06/24/21
08:18
SELB

Selecta Biosciences

$4.57 /

+0.02 (+0.44%)

Selecta Biosciences…

Selecta Biosciences announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline. Dr. de Silva is currently Chief Executive Officer and Director of AFYX Therapeutics.

ShowHide Related Items >><<
SELB Selecta Biosciences
$4.57 /

+0.02 (+0.44%)

SELB Selecta Biosciences
$4.57 /

+0.02 (+0.44%)

06/14/21 BTIG
Selecta Biosciences initiated with a Buy at BTIG
04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
SELB Selecta Biosciences
$4.57 /

+0.02 (+0.44%)

Over a month ago
Initiation
Selecta Biosciences initiated with a Buy at BTIG » 16:36
06/14/21
06/14
16:36
06/14/21
16:36
SELB

Selecta Biosciences

$4.99 /

+0.03 (+0.60%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Selecta Biosciences with a Buy rating and $10 price target. The analyst sees significant potential in the company's ImmTOR technology platform beyond the chronic refractory gout program. Zhong added that he believes SEL-212's clinical data to date have demonstrated "strong" efficacy and safety to support an FDA approval.

ShowHide Related Items >><<
SELB Selecta Biosciences
$4.99 /

+0.03 (+0.60%)

SELB Selecta Biosciences
$4.99 /

+0.03 (+0.60%)

04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
SELB Selecta Biosciences
$4.99 /

+0.03 (+0.60%)

SELB Selecta Biosciences
$4.99 /

+0.03 (+0.60%)

Hot Stocks
Selecta announcer paper on hepatic tolerogenic potential of ImmTOR » 08:09
06/01/21
06/01
08:09
06/01/21
08:09
SELB

Selecta Biosciences

$4.36 /

+0.01 (+0.23%)

Selecta Biosciences…

Selecta Biosciences announced the peer-reviewed publication of a study investigating the effects of ImmTOR nanoparticles in generating a tolerogenic environment in the liver. The data, published in a Frontiers in Immunology paper titled "Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles," demonstrate that ImmTOR induces a tolerogenic phenotype in all major resident antigen-presenting cell populations in the liver, resulting in modulation of hepatic T cell populations. These findings demonstrate the capability of Selecta's ImmTOR platform in promoting hepatic immune tolerance, providing support for the potential of ImmTOR for the treatment of autoimmune diseases affecting the liver. "Liver specific autoimmune diseases result from the loss of natural immunological tolerance to hepatic autoantigens," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "The data outlined in this publication demonstrate that ImmTOR could effectively enhances the tolerogenic environment of the liver by inducing tolerogenic antigen-presenting cells and was observed to be protective in an acute mouse model of autoimmune hepatitis. These data are of particular relevance to our primary biliary cholangitis program, and we look forward to building on these findings as we advance our first autoimmune program towards the clinic."

ShowHide Related Items >><<
SELB Selecta Biosciences
$4.36 /

+0.01 (+0.23%)

SELB Selecta Biosciences
$4.36 /

+0.01 (+0.23%)

04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
SELB Selecta Biosciences
$4.36 /

+0.01 (+0.23%)

SELB Selecta Biosciences
$4.36 /

+0.01 (+0.23%)

Hot Stocks
Selecta Biosciences expects cash to fund requirements into 2Q23 » 08:06
05/13/21
05/13
08:06
05/13/21
08:06
SELB

Selecta Biosciences

$3.01 /

+0.055 (+1.86%)

Selecta had $149.2…

Selecta had $149.2 million in cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2021, which compares to cash, cash equivalents, and restricted cash of $140.1 million as of December 31, 2020. Selecta believes its available cash, cash equivalents, marketable securities, and restricted cash will be sufficient to meet its operating requirements into the second quarter of 2023.

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

Earnings
Selecta Biosciences reports Q1 EPS (22c), consensus (12c) » 08:06
05/13/21
05/13
08:06
05/13/21
08:06
SELB

Selecta Biosciences

$3.01 /

+0.055 (+1.86%)

Reports Q1 revenue…

Reports Q1 revenue $11.1M, consensus $7.52M. "We are very pleased about the continued progress across all aspects of the company," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "We regained exclusive rights to our MMA program and now have two proprietary gene therapy programs to rapidly follow our ongoing empty capsid study. Additionally, we continue to progress our enzyme program, with an expected IND filing by the end of 2021 in IgA nephropathy, and topline data from the Phase 3 DISSOLVE program for SEL-212 anticipated in the second half of 2022."

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

04/29/21 Mizuho
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news
03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

SELB Selecta Biosciences
$3.01 /

+0.055 (+1.86%)

Recommendations
Mizuho sees 'minimal impact' to Selecta Biosciences from AskBio assumption news » 13:37
04/29/21
04/29
13:37
04/29/21
13:37
SELB

Selecta Biosciences

$3.25 /

-0.635 (-16.34%)

After Selecta Biosciences…

After Selecta Biosciences and Asklepios BioPharmaceutical announced that Selecta will assume all rights to the companies' collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia, Mizuho analyst Difei Yang said she sees "minimal impact" from the news and views it as "immaterial" to Selecta's valuation. Noting that MMA was the sole metabolic disease in AskBio's pipeline, Yang said she is not surprised that the company has decided to exit the indication following a strategic review. Yang has a Buy rating and $8 price target on Selecta shares.

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.25 /

-0.635 (-16.34%)

SELB Selecta Biosciences
$3.25 /

-0.635 (-16.34%)

03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
10/05/20 H.C. Wainwright
Selecta Biosciences price target lowered to $6 from $10 at H.C. Wainwright
SELB Selecta Biosciences
$3.25 /

-0.635 (-16.34%)

SELB Selecta Biosciences
$3.25 /

-0.635 (-16.34%)

Hot Stocks
Selecta Biosciences assume all rights to MMA program from AskBio » 08:37
04/29/21
04/29
08:37
04/29/21
08:37
SELB

Selecta Biosciences

$3.88 /

-0.03 (-0.77%)

Selecta Biosciences and…

Selecta Biosciences and Asklepios BioPharmaceutical announced an update to the companies' collaboration to evaluate gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia. Selecta will assume all rights to the MMA program and will continue to progress the MMA-101 and ImmTOR combination through clinical development. AskBio's decision to give all rights to Selecta is based on an internal strategic review and prioritization of its portfolio. Due to a manufacturing issue the company believes is related to a component sourced from a third-party, Selecta now expects that submission of the IND for MMA-101 and ImmTOR will be delayed until at least the fourth quarter of 2021. A detailed assessment of the manufacturing process is currently being conducted, and the Company expects to provide an update on program timelines as they are clarified. ImmTOR manufacturing continues to proceed smoothly, and there is no impact to any of Selecta's ImmTOR programs. The dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 empty vector capsid containing no DNA combined with ImmTOR, is currently underway and progressing as expected. The study, being conducted in healthy volunteers at the SGS Life Sciences Clinical Pharmacology Unit in Antwerp, Belgium, is designed to evaluate the safety and preliminary efficacy of ImmTOR in gene therapy. Selecta and AskBio intend to provide topline data in the fourth quarter of this year.

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.88 /

-0.03 (-0.77%)

SELB Selecta Biosciences
$3.88 /

-0.03 (-0.77%)

03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
10/05/20 H.C. Wainwright
Selecta Biosciences price target lowered to $6 from $10 at H.C. Wainwright
SELB Selecta Biosciences
$3.88 /

-0.03 (-0.77%)

SELB Selecta Biosciences
$3.88 /

-0.03 (-0.77%)

Over a quarter ago
Hot Stocks
Selecta Biosciences Chief Medical Officer buys 20K shares of common stock » 17:57
03/19/21
03/19
17:57
03/19/21
17:57
SELB

Selecta Biosciences

$4.58 /

+0.19 (+4.33%)

In a regulatory filing,…

In a regulatory filing, Selecta Biosciences disclosed that its Chief Medical Officer Peter Traber bought 20K shares of common stock in a total transaction size of $90K, boosting his stake by about 26%.

ShowHide Related Items >><<
SELB Selecta Biosciences
$4.58 /

+0.19 (+4.33%)

SELB Selecta Biosciences
$4.58 /

+0.19 (+4.33%)

03/12/21 William Blair
Selecta upgraded to Outperform ahead of catalysts at William Blair
03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
10/05/20 H.C. Wainwright
Selecta Biosciences price target lowered to $6 from $10 at H.C. Wainwright
SELB Selecta Biosciences
$4.58 /

+0.19 (+4.33%)

SELB Selecta Biosciences
$4.58 /

+0.19 (+4.33%)

Upgrade
Selecta upgraded to Outperform ahead of catalysts at William Blair » 07:09
03/12/21
03/12
07:09
03/12/21
07:09
SELB

Selecta Biosciences

$3.90 /

+0.005 (+0.13%)

William Blair analyst…

William Blair analyst Raju Prasad upgraded Selecta Biosciences to Outperform from Market Perform without a price target. The analyst believes data from Selecta's Phase I study of SEL-399, anticipated in Q4, has potential to drive "significant value." After a deep dive into the ImmTOR published literature to date, Prasad views Selecta's non-human primates data favorably and as supporting a positive risk/reward ratio going into the upcoming Phase I trial and future gene therapy studies with ImmTOR. Between now and 2022 the analyst sees "several catalysts that can drive the stock significantly."

ShowHide Related Items >><<
SELB Selecta Biosciences
$3.90 /

+0.005 (+0.13%)

SELB Selecta Biosciences
$3.90 /

+0.005 (+0.13%)

03/12/21 William Blair
Selecta Biosciences upgraded to Outperform from Market Perform at William Blair
01/26/21 Mizuho
Selecta Biosciences upgraded to Buy from Neutral at Mizuho
10/05/20 H.C. Wainwright
Selecta Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/01/20
Fly Intel: Top five analyst downgrades
SELB Selecta Biosciences
$3.90 /

+0.005 (+0.13%)

SELB Selecta Biosciences
$3.90 /

+0.005 (+0.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.